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Osteoarthritis (OA) is highly prevalent and a leading cause of disability worldwide. Despite the global
burden of OA, diagnostic tests and treatments for the molecular or early subclinical stages are still not
available for clinical use. In recent years, there has been a large shift in the understanding of OA as a
“wear and tear” disease to an inﬂammatory disease. This has been demonstrated through various studies
using MRI, ultrasound, histochemistry, and biomarkers. It would of great value to be able to readily
identify subclinical and/or sub-acute inﬂammation, particularly in such a way as to be appropriate for a
clinical setting. Here we review several types of biomarkers associated with OA in human studies that
point to a role of inﬂammation in OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Inﬂammatory osteoarthritis (OA) is a debilitating and highly
prevalent disease, but is often sub-clinical. There is an increasing
body of evidence that inﬂammatory and destructive responses of
the synovium play a major role in OA1. Moreover, the role of
inﬂammation in the illness of OA has been recognized through the
association of joint effusion with joint pain2. It is still unclear to
what extent inﬂammation is an initiator vs an outcome of the joint
destructive process3. Of particular interest is the emerging evi-
dence that the degree to which the immune and wound healing
responses can be activated in part controls the predisposition of an
individual to chronic diseases, among them OA. Despite the global
burden of OA, diagnostic tests and treatments for the molecular or
early subclinical stages are still not available for clinical use. It
would of great value to be able to readily identify subclinical and/or
sub-acute inﬂammation, particularly in such a way as to be
appropriate for a clinical setting. Here we review several types of
biomarkers associatedwith OA in human studies that point to a role
of inﬂammation in OA.: V.B. Kraus, Duke Molecular
ing, 300 N. Duke St., Durham,
-8907.
ternational. Published by Elsevier LGenetic and genomic markers
Increasingly, enrichment strategies are being used in clinical
trials to select a study population inwhich detection of a drug effect
is more likely than it would be in an unselected population
(prognostic enrichment), or to increase the likelihood of predicting
a response (predictive enrichment). In December 2012, the US Food
and Drug Administration (FDA) published a draft guidance
describing enrichment strategies to support approval of drugs and
biological products4. To date, labeling of more than 100 approved
drugs contain information on companion diagnostics, all in the
form of genomic biomarkers5. Genomic selection to predict a
response has primarily been used in hematology/oncology and only
4% of the companion diagnostics are currently in the ﬁeld of
rheumatology6. However, a genomic strategy to identify a subset
(4%) of patients with cystic ﬁbrosis likely to respond to ivacaftor
(via speciﬁc mutations of the CFTR gene) led to the recent FDA
approval of this drug7. In addition, the FDA has recently approved
several new drugs and drug combinations8e10 for the treatment of
speciﬁc hepatitis C genotypes on the basis of companion genomic
tests. A number of genetic/genomic markers are emerging in OA
that relate to inﬂammatory phenotypes that might be similarly
exploited in the future for enriching for speciﬁc patient subsets for
trials and eventually selecting patients for speciﬁc clinical
treatments.
For instance, several studies suggest that a proportion of the
genetic susceptibility to OA may be encoded by variations in innatetd. All rights reserved.
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antibiotics has shifted the role of the innate immune system from
being protective against infectious diseases to intensifying age-
related chronic diseases16,17. The fact that this may be the case
has recently been demonstrated by the emerging story related to
the forkhead-box class O (FOXO) genes, which have been found to
mediate the inﬂammatory, apoptosis, and barrier function re-
sponses of keratinocytes exposed to bacteria18. In particular, FOXO1
promotes wound healing by regulating the expression of trans-
forming growth factor-beta (TGF-b) and playing a protective role
against oxidative stress19. FOXO1 and FOXO3 were also found to be
expressed in human cartilage, and exposure of pro-inﬂammatory
cytokines suppressed the activity of FOXO1 in chondrocytes20. In
addition, chondrocytes with reduced expression of FOXO tran-
scription factors were more susceptible to apoptosis when exposed
to oxidative stress21. The injury of articular cartilage induces
changes in genes associated with cell signaling, response to injury,
and wound healing22. Recently, the pro-apoptotic gene, PUMA, has
been shown to be activated by the c-Jun N-terminal kinase (JNK)/c-
Jun pathway in the regulation of chondrocyte apoptosis in cartilage
of patients with OA23. Moreover, theWnt signaling pathway, which
is involved in both cartilage and bone tissue homeostasis24, was
found to be up-regulated while its inhibitor (FRZB) was down-
regulated in cartilage from joints with moderate to severe OA
damage22. Wnt signaling and DNA repair pathways have also been
identiﬁed to be signiﬁcantly correlated with articular cartilage
healing25.
A well-validated gene expression method has identiﬁed higher
levels of interleukin (IL)-1b expression in peripheral blood leuko-
cytes (PBLs) in patients with knee OA in association with increased
pain and greater risk of radiographic progression of OA26. The
expression of four microRNAs (miRNAs) (miR-146a, miR-155, miR-
181a, and miR-223), which have been reported to be expressed in
immune cells and are responsible for regulating inﬂammation,
were signiﬁcantly higher in the peripheral blood mononuclear cells
(PBMCs) of patients with OA compared to the PBMCs of healthy
controls27. In another study, plasma concentrations of miR-132
were signiﬁcantly higher in healthy controls compared to pa-
tients with either OA or rheumatoid arthritis (RA)28. In addition,
microarray analysis of blood samples from healthy controls and
patients with OA identiﬁed six genes signiﬁcantly down-regulated
in mild OA (heat shock 90 kDa protein 1, alpha; inhibitor of kappa
light polypeptide gene enhancer in B-cells, kinase complex-
associated protein; IL-13 receptor, alpha 1; laminin, gamma 1;
CXCL4; and tumor necrosis factor-inducible gene (TSG)-6)29, many
of which play an important role in inﬂammatory cascades. Given
the role that genomic companion testing has had in personalized
treatments, these genetic markers may pave the path for the
development of novel therapeutic targets to treat a subset of pa-
tients with OA.
Macrophages
The human body swiftly reacts in response to acute foreign in-
trusions or injury in a very complex and organized manner via the
innate immune system30. However, low-level inﬂammatory stim-
ulation may also affect the body and cause a state of chronic
inﬂammation. OA is increasingly recognized as a process involving
low grade inﬂammation, often subclinical31, that is predictive of
articular chondropathy and OA progression32e35.
A critical aspect of joint inﬂammation in OA involves synovial
macrophages and macrophage-produced cytokines that drive
aggrecanases, matrixmetalloproteinases, and other destructive and
inﬂammatory responses36. These critical mediators of joint
destruction may be used as tools to assess disease activity andseverity. We demonstrated that the proﬁle of cytokines in the OA
joint is consistent with macrophage-mediated inﬂammasome
activation37. Interestingly, the synovial ﬂuid (SF) concentration of
uric acid in these OA knees was strongly associated with the con-
centration of several inﬂammatory cytokines. Uric acid is the ca-
nonical trigger of the macrophage-mediated inﬂammasome
activity in gout38 and is able to induce cytokine production by
macrophages39. Additional supporting evidence for a potential role
of uric acid in OA has been demonstrated by the effect monosodium
urate crystals have on decreasing chondrocyte viability and func-
tion in gout40.
Targeting activatedmacrophages as a treatment for OA has been
previously proposed41e43. Similarly, the released proteins and cy-
tokines of activated macrophages have great potential to become
diagnostic biomarkers for OA. Our recent etarfolatide imaging
study, which targets activated but not resting macrophages44,
demonstrated the preferential localization of activated macro-
phages to painful andmore severely affected osteoarthritic knees33.
The macrophage markers CD14 and CD163 measured in the blood
sera/plasma and SF were associated with etarfolatide uptake,
radiographic OA severity and progression, and joint symptoms34.
YKL-40, a member of the chitinase family, is a glycoprotein that is
secreted mostly from macrophages45,46 and chondrocytes47 and
has been found to be elevated in the SF of patients with RA and
OA48. Moreover, the median value of SF YKL-40 was greater in pa-
tients withmoderate/severe arthritis when compared to thosewith
none/mild arthritis48. Taken together, these results support the
involvement of macrophages in OA with activation of the innate
immune response in OA pathology and progression.
Complement
As part of the innate immune system, the complement system,
as inferred in its name, complements and assists antibodies and
phagocytic cells with the clearance of foreign objects49. The com-
plement system can be activated by several different pathways,
including bymany components of the cartilage extracellular matrix
(reviewed byHsueh et al.50). One proteomic study identiﬁed several
complement proteins that were differentially expressed between
healthy and OA knee SF samples51. In another proteomic study,
complement components were found to be modulated in sera of
patients with moderate and severe OA52. In particular, concentra-
tions of C3a and C5b-9 have been found to be signiﬁcantly higher in
the SF from patients with early-stage OA in comparison to those
from healthy individuals53. In addition, expression of transcripts
encoding the complement effectors C7, C4A, factor B, C9, and C5
was signiﬁcantly higher, while factor H, C4-binding protein, C1
inhibitor, and clusterin, which are complement inhibitors, were
lower in synovial membranes of patients with OA in comparison to
those from healthy individuals53. Interestingly, cartilage oligomeric
matrix protein (COMP), which is elevated in the sera54e56 and
SF57,58 of patients with OA, can also activate the complement sys-
tem59,60. The involvement of complement activation in OA is
consistent with its involvement in several other chronic inﬂam-
matory diseases, including RA61,62, atherosclerosis63,64,
Alzheimer's65e67, and age-related macular degeneration68,69.
C-reactive protein
C reactive protein (CRP) is a central component of the innate
immune inﬂammatory response; by binding to the cell surface of
dead or dying cells and some bacteria it leads to the activation of
the complement system70. The synthesis of CRP is mediated by
factors released by macrophages and adipocytes. CRP also leads to
the promotion of pro-inﬂammatory cytokines, which increases the
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heart failure72, and has been associated with the risk of developing
coronary artery disease73, head and neck squamous cell carcinoma
mortality74, and inﬂammatory bowel disease75. Several studies
have also sought to establish a connection between levels of serum
CRP and OA76. A recent meta-analysis of 32 studies revealed sta-
tistically signiﬁcant differences in serum CRP between patients
with OA and healthy controls. The study also revealed that CRP was
signiﬁcantly associated with pain and decreased physical function,
but not radiographic OA77. In studies that have adjusted for body
mass, CRP has been shown to be independently associated with
OA78, while other studies have not proven CRP to be independently
associated with OA79,80. The meta-analysis study by Jin and col-
leagues77 also compared studies that accounted for BMI from those
that did not and concluded that the association of CRP with OAwas
independent of BMI.
Cytokines
Cytokines are small proteins released from a wide array of cells,
including immune cells (macrophages, B lymphocytes, T lympho-
cytes, mast cells, natural killer cells, epithelial cells, endothelial
cells, dendritic cells, ﬁbroblasts, and stromal cells)81,82. Various cells
utilize cytokines, chemokines (chemotactic cytokines), and adipo-
kines (cytokines released by adipose tissue) as part of the inﬂam-
matory response to regulate cell signaling and interactions within
the cell itself and between other cells83,84. Cytokines can have
either pro-inﬂammatory or anti-inﬂammatory properties and often
work concordantly to maintain cell homeostasis85. We have shown
that the concentrations of key SF cytokines (IL-1a, IL-18 and tumor
necrosis factor (TNF)-a) were associated with the level of OA
severity; baseline IL-18 also predicted OA progression37. Serum
levels of IL-6 and TNF-a have also been associated with the prev-
alence of joint space narrowing and prediction of knee cartilage
loss86. Serum TNF-a levels have effectively been used to monitor
the efﬁcacy of various OA treatments in rabbits87. However, in a
multi-center, randomized, double blind, placebo-controlled trial,
injection of anti-TNF-a agents did not show any improvement in
patients with unmanageable hand OA88. Soluble TNF-a receptor
levels were decreased in the SF and plasma of patients with OA in
comparison with healthy controls, with SF levels being negatively
correlated with joint symptoms89 evaluated by the Western
Ontario and McMaster University Osteoarthritis Index (WOMAC)
questionnaire. Recently, the activity of the protein encoded by TSG-
6, which is an anti-inﬂammatory protein that is upregulated in
response to the pro-inﬂammatory cytokines TNF and IL-190, and
was previously detected in patients with arthritis91, has been
shown to be associated with progression of OA after 3-year follow-
up in a study of 91 patients92. In a small pilot study, Vangsness
et al.93 showed that higher levels of SF IL-2, IL-5, and monocyte
chemoattractant protein (MCP)-1 were associated with greater
degrees of OA severity. SF levels of IL-6, IL-13, and macrophage
inﬂammatory protein (MIP)-1bwere elevated in patients with end-
stage knee OA while granulocyte colony-stimulating factor (G-CSF)
levels were lower when compared to SF levels of healthy controls94.
From a prospective population-based study of 908 healthy
middle-aged British women, individuals with higher age and
baseline body mass index (BMI) and increased serum IL-6 after 5-
year follow-up were more likely to be diagnosed with radio-
graphic knee OA at their 10-year follow-up95. Given the association
of obesity with OA96,97, it is of interest that patients with knee OA
have increased levels of IL-6 and soluble IL-6 receptor released from
the infrapatellar fat pad of the knee compared with subcutaneous
adipose tissue98. Weight loss and increased physical activity in
obese elderly patients with OA decreased levels of soluble TNFaReceptor 1 and increased physical function99. Exercise has also
been shown to increase both intraarticular and peri-synovial con-
centrations of anti-inﬂammatory IL-10 in women with knee OA100.
Chemokines
Chemokines are a class of small protein cytokines that act as
chemoattractants to guide cells tomigrate to a speciﬁc location, and
in the context of inﬂammation, toward the site of injury or path-
ogenic invasion82. Interferon gamma inducible protein 10, also
known as CXCL-10, is a chemokine that has been shown to be
inversely associated with radiographic knee OA in both plasma and
SF62. Serum fractalkine, or CX3CL1, has been shown to be signiﬁ-
cantly elevated in patients with knee OA in comparison to the sera
from healthy individuals, while both serum and SF concentrations
of the chemokine were associated with KL scores101. SF CXCL12, but
not serum CXCL12, was associated with radiographic severity of
OA102. A recent study has demonstrated the feasibility of using
serum and SFMCP-1, also known as chemokine ligand 2 (CCL2), as a
biomarker for self-reported pain and physical disability in patients
with knee OA103. To further support the role of macrophages in OA-
related inﬂammation, MCP-1 has been shown to increase the
recruitment of macrophages into adipose tissue104 and athero-
sclerotic lesions105. SF levels of macrophage derived chemokine
(MDC) and interferon gamma-induced protein (IP-10) were
elevated in patients with end-stage knee OA, while eotaxin levels
were lower when compared to SF levels of healthy controls94.
Adipokines/Hormones
A number of adipose tissue-secreted hormones mediate in-
ﬂammatory effects106,107 and cartilage catabolism108e110 in OA.
Plasma adipokines adiponectin, which is responsible for modu-
lating metabolic processes, and leptin, a regulator of fat storage,
have been shown to be positively associated with joint symptom
burden, while the glucose modulating adipokine, adipsin, was
lower in patients with hip and knee OA111. Adipsin is also known as
complement factor D and is responsible for activating the alterna-
tive pathway of the complement system112. Serum adiponectin
levels have also been associated with radiographic hand OA pro-
gression after 6-year follow-up113. Leptin is believed to play an
important role in the pathogenesis of OA via its stimulation of
anabolic functions of chondrocytes in cartilage114. Serum leptin
levels were also associated with prevalent and incident knee OA in
the Study of Women's Health Across the Nation (SWAN) cohort115.
Serum leptin measured at baseline has been associated with
increased levels of bone formation biomarkers (osteocalcin and
procollagen type I N-terminal propeptide (PINP)) after 2-year
follow-up116. In addition, baseline soluble leptin receptor was
associated with lower levels of procollagen type II N-terminal
propeptide (PIIANP) and decreased cartilage volume116. Visfatin
(also known as nicotinamide phosphoribosyltransferase (Nampt)),
which is an adipokine and enzyme involved in the metabolism of
nicotinate and nicotinamide, has recently been suggested to be a
therapeutic target for OA given its role in chondrocyte and osteo-
blast activation117. As an inﬂammatory biomarker, levels of SF vis-
fatin were signiﬁcantly greater in patients with knee OA compared
to control subjects118. In addition, SF visfatin was positively corre-
lated with the cartilage degradation markers collagen II (CTX-II)
and aggrecan (AGG1 and AGG2) and was signiﬁcantly elevated in
more severe knee OA grades (Kellgren Lawrence 4 vs 3)118. In
middle-aged women, lower levels of serum estradiol, which is a
hormone that has anti-inﬂammatory properties119, and the urinary
estrogen metabolite 2-hydroxyestrone were associated with both
the prevalence and incidence of knee OA120.
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Given the inverse association of OA susceptibilitywith the ability
of cartilage to repair itself121, the subset of patients with inﬂam-
matory OA phenotypes are likely the ones most at risk for pro-
gression and symptoms. Moreover, given the wealth of agents
available for treating autoimmune arthritides characterized by
ﬂagrant inﬂammation, there is a high likelihood that some of these
agents, in appropriate dosing schemes, could be employed to treat
the subset of patients with inﬂammatory OA. This OA subgroup
would therefore seem to be an ideal one for which to develop al-
gorithms and tools for reliable identiﬁcation such as the artiﬁcial
neural network model recently developed by Heard and col-
leagues122. The descriptions above brieﬂy summarize associations
of inﬂammatory components with OA that could in future be
exploited to assist with identiﬁcation of patients for the most
appropriate therapy. This however, will require tests with known
precision and predictive capability (sensitivity, speciﬁcity, positive
and negative predictive value) that represents a long develop-
mental pathway before any of the researchﬁndings described above
could be translated into use in clinical trials or practice. Neverthe-
less, a biomarker qualiﬁcation project in OA is ongoing123 that could
serve as a paradigm for the qualiﬁcation of inﬂammatorymarkers is
OA. Although a number of OA-related biomarkers emanating from
joint tissue have been identiﬁed, only a minority have been quali-
ﬁed in the context of inﬂammation due to the limitation of phe-
notyping tools to identify the subclinical inﬂammation in OA1.
Nevertheless, it has been possible to identify numerous inﬂamma-
tory molecules and pathways in association with OA. This un-
derscores the generalizability of inﬂammation in OA, albeit often
subacute or subclinical. As we learn more about the genetic control
of inﬂammation and wound healing in OA we will undoubtedly
discover key targets for therapy in addition to being able to better
subset patients for trials and eventually, speciﬁc therapies.
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